INOVIO Pharmaceuticals, Inc., a biotechnology company focused on DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases, has announced its intention to conduct a public offering of its common stock. The offering includes shares and accompanying Series A and Series B warrants, with all securities to be sold by INOVIO. Piper Sandler & Co. will act as the sole book-running manager for the offering. The company has filed a shelf registration statement with the SEC, and the offering will proceed based on market conditions. A preliminary prospectus supplement will be filed with the SEC and made available to the public.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。